

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2003/009892
International Filing Date : 5 September 2003 (05.09.2003)
Priority Date(s) Claimed : 06 September 2002 (06.09.2002)
Applicant(s) (DO/EO/US) : Enno KLUSSMANN, et al.

Title: NEW SPLICING VARIANT OF A PROTEIN KINASE A ANCHOR PROTEIN
AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- ☒ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
- ☐ within three months of the filing date of a national application other than a CPA under § 1.53(d);
 - ☒ within three months of the actual filing date of the national phase of a PCT application; OR
 - ☐ before the mailing of a first substantive office action (including after filing of an RCE).
- ☐ Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
- a final rejection under 37 C.F.R. 1.113;
 - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
 - a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

- ☐ the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
- ☐ a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).

☐ Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:

- ☐ a final action under 37 C.F.R. § 1.113;
- ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
- ☐ OR a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

- ☐ Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. _____, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- ☒ Copies of materials listed but not attached were cited in an international search report dated February 18, 2004.
- ☐ Not required by 37 CFR § 1.98.
- ☐ Copies of the materials listed are attached (except for the foregoing).

Non-English Language References

- ☒ An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
- ☐ A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
- X = document of particular relevance when it is taken alone
 Y = document of particular relevance when it is combined with another such document
 A = document defining the general state of the art
 O = non-written disclosure
 P = intercalated document
 T = document cited to understand the theory or principle underlying the invention
 E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
 D = cited in the application
 L = cited for another reason
 & = publication of member of same patent family
- ☐ Translation of other relevant information on foreign search report

Other Information

Payment of Fees Due (If Any):


- ☐ A check for \$_____ covering the fee identified above is attached.
- ☐ Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

10/526768

PT12 PCT/PTO 07 MAR 2005

☒ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: GULDE-0058

Date: March 7, 2005

AJZ:ssr

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	USNP of PCT/EP2003/009892
		Filing Date	5 September 2003 (05.09.2003)
		First Named Inventor	Enno KLUSSMANN, et al.
		Group Art Unit	unknown
		Examiner Name	unknown
		Attorney Docket Number	GULDE-0058
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	001	KLUSSMANN, ET AL.: "CHARACTERIZATION OF A NEW SPLICE VARIANT OF AKAP18: ITS POTENTIAL INVOLVEMENT IN VASOPRESSIN-MEDIATED WATER REABSORPTION" NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, vol. 362, no. 4-5, 2000, page R28	
	002	KLUSSMANN, ET AL: "ROLE AND IDENTIFICATION OF PROTEIN KINASE A ANCHORING PROTEINS IN VASOPRESSIN MEDIATED AQUAPORIN-2 TRANSLOCATION" KIDNEY INTERNATIONAL, vol. 60, 2001, pages 446-449	
	003	TROTTER ET AL.: "ALTERNATIVE SPLICING REGULATES THE SUBCELLULAR LOCALIZATION OF A -KINASE ANCHORING PROTEIN 18 ISOFORMS" THE JOURNAL OF CELL BIOLOGY, vol. 147, NO. 7, 27 December 1999	
	004	KLUSSMANN ET AL.: "PROTIEN KLINASE A ANCHORING PROTEINS ARE REQUIRED FOR VASOPRESSIN-MEDIATED TRANSLOCATION OF AQUAPROIN-2 INTO CELL MEMBRANES OF RENAL PRINCIPAL CELLS" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 8, 19 February 1999	
	005	OLIVERIA ET AL.: "IMAGING KINASE-AKAP79-PHOSPHATASE SCAFFOLD COMPLEXES AT THE PLASMA MEMBRANE IN LIVING CELLS USING FRET MICROSCOPY" THE JOURNAL OF CELL BIOLOGY, vol. 160, no. 1, 1 January 2003, pages 101-112	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.